AbbVie: Clinical Trials

1,253 trials sponsored by AbbVie, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

721 completed, 166 recruiting, 151 active not recruiting, 111 terminated. 337 Phase 1, 317 Phase 2, 305 Phase 3, 67 Phase 4, 24 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 1337Completed 183, Active not recruiting 50, Terminated 50, Recruiting 38, Withdrawn 10, Not yet recruiting 5, Unknown 1
Phase 2317Completed 142, Recruiting 72, Active not recruiting 48, Terminated 35, Not yet recruiting 10, Withdrawn 8, Enrolling by invitation 2
Phase 3305Completed 200, Active not recruiting 45, Recruiting 29, Terminated 13, Withdrawn 8, Not yet recruiting 5, Enrolling by invitation 3, Unknown 2
Phase 467Completed 39, Recruiting 9, Terminated 7, Unknown 7, Active not recruiting 2, Withdrawn 2, Not yet recruiting 1
Not applicable24Completed 15, Active not recruiting 3, Unknown 3, Not yet recruiting 1, Recruiting 1, Withdrawn 1
Early Phase 14Active not recruiting 1, Completed 1, Not yet recruiting 1, Terminated 1

Follow AbbVie: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Upadacitinib, Placebo for Upadacitinib - Non-Segmental Vitiligo
Phase 3Not yet recruitingAbbVie1542027-01-282026-10-27
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer
Phase 3Not yet recruitingAbbVie6602027-01-062026-10-05
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2Not yet recruitingThe Lymphoma Academic Research Organisation442026-12-312026-07-31
A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.
ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis
Phase 2 / Phase 3Not yet recruitingAbbVie5802026-12-112026-11-12
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
ABBV-722, Upadacitinib - Rheumatoid Arthritis
Phase 2Not yet recruitingAbbVie2502026-12-072026-11-10
A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis
Risankizumab, ABBV-295, ABBV-295 Placebo - Moderate to Severe Psoriasis
Phase 2Not yet recruitingAbbVie1052026-12-032026-11-12
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma
Phase 1 / Phase 2Not yet recruitingUniversitätsklinikum Hamburg-Eppendorf2202026-12-012026-05-20
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL)
Phase 2Not yet recruitingThe Lymphoma Academic Research Organisation552026-12-012026-09-10
Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Upadacitinib, Placebo - JAK1 GOF, STAT1 GOF
Phase 1 / Phase 2Not yet recruitingLisa Satter302026-12-012026-11-12
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma
Phase 3Not yet recruitingAbbVie5202026-11-302026-07-27
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis
Phase 3Not yet recruitingAbbVie3702026-11-292026-08-28
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Alveltamig, Atezolizumab, ABBV-706 - Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
Phase 2Not yet recruitingAbbVie802026-11-202026-10-26
M4 Receptor PET Radioligand Validation Study in Healthy Adults
[11C]ABBV-112i - Healthy Volunteers
Early Phase 1Not yet recruitingAbbVie62026-11-102026-11-12
A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult Participants.
ABBV-1606, Placebo - Healthy Volunteer
Phase 1Not yet recruitingAbbVie402026-11-102026-11-13
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer
ABBV-706, Tarlatamab, Atezolizumab - Extensive Stage-Small Cell Lung Cancer
Phase 2Not yet recruitingAbbVie802026-11-042026-10-26
Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults
ABBV-1162, Placebo - Healthy Volunteers
Phase 1Not yet recruitingAbbVie402026-11-022026-09-22
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer
RecruitingAbbVie5002026-10-212026-10-27
Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis
Upadacitinib - UC - Ulcerative Colitis
Phase 4Not yet recruitingUniversity of California, San Francisco502026-10-152026-09-24
A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants
Trosunilimab - Healthy Volunteer
Phase 1RecruitingAbbVie602026-10-132026-11-09
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA - Upper Facial Lines, Glabellar Lines
Phase 2RecruitingAbbVie3002026-10-082026-11-05

Showing 20 of 1253. Sign in to see all of them.

Conditions studied

Neoplasms (143)  ·  Hepatitis C (87)  ·  Hepatitis C, Chronic (80)  ·  Leukemia, Myeloid, Acute (68)  ·  Psoriasis (60)  ·  Crohn Disease (57)  ·  Arthritis, Rheumatoid (56)  ·  Colitis, Ulcerative (47)  ·  Carcinoma, Non-Small-Cell Lung (42)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (42)  ·  Multiple Myeloma (41)  ·  Recurrence (41)  ·  Parkinson Disease (34)  ·  Dermatitis, Atopic (33)  ·  Arthritis, Psoriatic (29)

Interventions

venetoclax (137)  ·  upadacitinib (72)  ·  risankizumab (71)  ·  Adalimumab (54)  ·  Dexamethasone (46)  ·  Ribavirin (40)  ·  ombitasvir (40)  ·  dasabuvir (39)  ·  paritaprevir (39)  ·  Carboplatin (31)  ·  glecaprevir and pibrentasvir (29)  ·  Azacitidine (28)  ·  Rituximab (28)  ·  budigalimab (28)  ·  Botulinum Toxins, Type A (25)

Countries

United States (726)  ·  Spain (278)  ·  Canada (271)  ·  Germany (256)  ·  Japan (232)  ·  Australia (228)  ·  France (222)  ·  United Kingdom (213)  ·  Italy (210)  ·  Israel (188)  ·  Poland (160)  ·  South Korea (159)  ·  Belgium (158)  ·  Taiwan (144)  ·  Puerto Rico (142)

Top investigators

Eric Cohen, MD (4)  ·  Andrey Strugovschikov, MD (3)  ·  Armen Asatryan, MD (3)  ·  Emily Dumas, PhD (3)  ·  Susumu Matsuki, BS (3)  ·  Yan Luo, MD (3)

Results publications

PMID 40875187, PMID 30739368, PMID 36754548, PMID 30977945, PMID 37982966, PMID 30012435, PMID 30923816, PMID 37945286, PMID 31568620, PMID 34041702, PMID 30529905, PMID 31610021, PMID 35829925, PMID 31054118, PMID 31667790, PMID 34878624, PMID 36715850, PMID 37308218, PMID 30868245, PMID 33115760, PMID 36125701, PMID 36178584, PMID 31023700, PMID 34921669, PMID 35174470, PMID 36794283, PMID 38620092, PMID 38683479, PMID 38863178, PMID 39624020, PMID 41264726, PMID 41763462, PMID 27411694, PMID 29290251, PMID 29476499, PMID 29909549, PMID 29982805, PMID 32621325, PMID 32945631, PMID 33650259, PMID 33963686, PMID 35714786, PMID 37043227, PMID 37224198, PMID 37247226, PMID 37368103, PMID 38492903, PMID 38492904, PMID 38982567, PMID 39054592

NIH funding

2023 (61), 2016 (43), 2015 (41), 2014 (38), 2019 (31), 2017 (26), 2025 (21), 2018 (18), 2009 (4), 2008 (2), P30CA060553 (2), 4UH3TR003908 (1), K08AR080844 (1), K23AR080043 (1), P30CA072720 (1)